Psyence Biomedical Ltd. (PBM) Stock Score, Valuation & Financial Research
Psyence Biomedical Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for PBM
Psyence Biomedical Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 4.79. These figures are a research snapshot, not a buy or sell recommendation.
What Psyence Biomedical Ltd. does
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Company business and revenue
Research reporting period: 2026-03-31. A research update is not a new financial filing.
How the company makes money
Psyence Biomedical Ltd. is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of nature-derived psilocybin and ibogaine-based psychedelic medicines for the treatment of mental health disorders, particularly in palliative care settings, and it relies on capital raises to fund these operations.
Products and services
- The company is developing NPX-5, a nature-derived psilocybin product candidate, for use in clinical trials targeting adjustment disorder in palliative-care cancer patients.
Customer types
Palliative care patients with mental health disorders.
Suppliers, materials and equipment
- Southern Star Research — A contract research organization engaged for the execution of clinical trials. Source
Business relationships and partnerships
- PsyLabs Ltd. — The company maintains equity interests in and licensing agreements with PsyLabs, a federally licensed producer of psychedelic active pharmaceutical ingredients. Source
Business strengths to evaluate
- Focus on nature-derived, non-synthetic psychedelic therapeutics Source
Business risks and research considerations
- History of operating losses and dependence on future capital raises Source
- Regulatory uncertainty and clinical trial failure risks Source
Sources: Company research source · PsyLabs Ltd. · Southern Star Research · Focus on nature-derived, non-synthetic psychedelic therapeutics · History of operating losses and dependence on future capital raises
Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
PBM financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 4.79
- Market capitalization:
- 91.1K (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -26.25M
- Free cash flow:
- USD -8.64M
- Cash:
- USD 7.2M
- Total debt:
- USD 0.00
- EPS:
- USD 1.64
- P/E ratio:
- 2.9x
What stands out
- Free cash flow is USD -8.64M, negative for the stored period.
- The balance sheet shows USD 7.2M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 7.2M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for PBM
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can PBM fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is PBM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for PBM to reach sustainable profitability?
- What does the current share basis reconciled warning mean for the reliability or interpretation of PBM's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-12.
Research-input completeness: 64% of the scoring inputs required for this public page are currently available.
How to research PBM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.